UH Seidman Cancer Center Leadership
President and Scientific Officer of University Hospitals Seidman Cancer Center
Dr. Teknos leads the development of strategic, business and marketing plans for UH Seidman, including cancer-related palliative care, integrative care and interface with UH Hospice care. He oversees all inpatient and ambulatory cancer care delivered at facilities across the UH system. Dr. Teknos provides leadership of UH Seidman’s academic components and the Clinical Trials Unit. He directs UH Seidman’s involvement in the Case Comprehensive Cancer Center.
Dr. Teknos earned his medical degree from Harvard Medical School. He completed his otolaryngology residency at Massachusetts Eye and Ear Infirmary/Harvard Combined Program, Boston, and a fellowship in head and neck oncology, skull base and microvascular reconstruction at Vanderbilt University Medical Center in Nashville.
Contact Dr. Teknos at 440-596-5597
Chair, Surgical Oncology Quality Committee, UH Cleveland Medical Center, Interim Chief Medical Officer, UH Seidman Cancer Center and Professor of Surgery, Case Western Reserve University School of Medicine
Responsible for quality and inpatient clinical services for the cancer hospital.
Contact Dr. Hardacre at 216-844-7047
Medical Oncologist, UH Seidman Cancer Center; Francis Wragg Ingalls Professor of Cancer Genetics, Case Western Reserve University School of Medicine
A team of researchers published findings in the April issue of Science Translational Medicine on the effects of aspirin on colorectal cancer risk in people with the gene 15-hydroxyprostaglandin dehydrogenase (15-PGDH) RNA. The study, which included nearly 128,000 participants, found that people with high levels of 15-PGDH in their colons could cut their colorectal cancer risk in half by taking aspirin. Researchers now hope to develop a cost-effective test for measuring the levels of 15-PGDH in the colon to determine which patients would benefit from aspirin therapy.
Contact Dr. Markowitz at 440-503-6840
Director, Thoracic Oncology Program, Rosalie and Morton A. Cohen Chair in Oncology, Endowed Director of the Gries Center for Cancer Drug Development, UH Seidman Cancer Center; and Professor of Medicine, Case Western Reserve University School of Medicine
The Research team published two studies that have the potential to advance the treatment of small cell lung cancer (SCLC), one of the fastest-growing cancers
The first study, published in the Journal of Thoracic Oncology, found a new mutation in SCLC, called RET, that was linked to rapid cell growth. Examining specimens in its database of metastatic SCLC tumors, the team discovered that the RET protein was sensitive to two new targeted therapies, ponatinib and vandetanib. The second study, published in PLOS One, focused on analyzing SCLC tumors to examine drug sensitivity to predict which drugs would be most effective at slowing tumor growth.
Contact Dr. Dowlati at 216-844-1228